Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

Bone Marrow Transplantation volume 30, pages 327–329 (2002)Cite this article

Abstract

In this case report we describe a novel treatment with two chimeric monoclonal antibodies (MoAb) targeting the autoimmune B cell clone responsible for bullous pemphigoid (BP) as a manifestation of steroid refractory chronic graft-versus-host disease (GVHD) that developed after unrelated cord blood transplantation. Monitoring the BP-specific circulating antibodies and CD25-expressing activated T lymphocyte subset led us to combine anti-CD20 (Rituximab) mediated B cell ablation with anti-CD25 (Daclizumab) therapy to block CD4+ T cell help. Complete clinical and serologic response was achieved within 4 weeks of initiation of therapy allowing global immunosuppression to be dramatically reduced.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Domloge-Hultsch N, Gammon WR, Briggaman RA et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease J Clin Invest 1992 90: 1628 1633

    Article  CAS  Google Scholar 

  2. Grillo-Lopez AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma Semin Oncol 1999 26 (Suppl. 14): 66 73

    Google Scholar 

  3. Ratanatharathorn V, Carson E, Reynolds C et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease Ann Intern Med 2000 133: 275 279

    Article  CAS  Google Scholar 

  4. Saleh MN, Gutheil J, Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia Semin Oncol 2000 27 (Suppl. 12): 99 103

    Google Scholar 

  5. Stasi R, Pagano A, Stipa E, Amadori S . Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 2001 98: 952 957

    Article  CAS  Google Scholar 

  6. Ahrens N, Kingreen D, Seltsam A, Salama A . Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab) Br J Haematol 2001 114: 244 245

    Article  CAS  Google Scholar 

  7. Zecca M, De Stefano P, Nobili B, Locatelli F . Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia Blood 2001 97: 3995 3997

    Article  CAS  Google Scholar 

  8. Waldmann TA, O'Shea J . The use of antibodies against the IL-2 receptor in transplantation Curr Opin Immunol 1998 10: 507 512

    Article  CAS  Google Scholar 

  9. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease Blood 2000 95: 83 89

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by The Lisa Stafford Memorial Research Prize, The National Marrow Donor Program-Marrow Transplant Research Grant (PSz), RO1-Al-47258-01A1 (RH), N01-HB-67141, N01-HB-67138 (JK).

Author information

Authors and Affiliations

  1. Department of Pediatrics, Pediatric Stem Cell Transplant Program, Duke University Medical Center, Durham, NC, USA

    P Szabolcs, M Reese & J Kurtzberg

  2. Dermatology Branch, DCS, NCI, NIH, Bethesda, MD, USA

    KB Yancey

  3. Department of Dermatology, Duke University Medical Center, Durham, NC, USA

    RP Hall

Authors
  1. P Szabolcs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Reese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. KB Yancey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. RP Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Kurtzberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szabolcs, P., Reese, M., Yancey, K. et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 30, 327–329 (2002). https://doi.org/10.1038/sj.bmt.1703654

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703654

Keywords

This article is cited by

Search

Advanced search

Quick links